Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus
- 16 October 2006
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 20 (10), 1188-1193
- https://doi.org/10.1111/j.1468-3083.2006.01698.x
Abstract
Background Oral terbinafine and oral itraconazole are two of the most common agents used for the treatment of toenail dermatophyte onychomycosis. Despite the fact that diabetic patients are more likely to have onychomycosis than normal individuals are, there is little research into the efficacy of standard oral regimens of terbinafine and itraconazole for onychomycosis in the diabetic population. Study design We present a prospective, randomized, single‐blind, parallel group, comparator‐controlled, multi‐centre study designed to assess the efficacy of the pulse itraconazole (200 mg twice daily, 1 week on, 3 weeks off, for 12 weeks) vs. continuous terbinafine (250 mg once daily for 12 weeks) oral therapies in the treatment of dermatophyte toenail distal and lateral subungual onychomycosis (DLSO) in the diabetic population. Efficacy parameters Primary efficacy measures included mycological cure rate (negative KOH and culture) and effective cure (mycological cure plus nail plate involvement of 10% or less) at Week 48. Results At Week 48, mycological cure was attained by 88.2% (30 of 34) and 79.3% (23 of 29) of patients in the itraconazole and terbinafine groups, respectively (P not significant). Effective cure (mycological cure with ≤ 10% of nail plate involvement) was attained by 52.9% (18 of 34) of the itraconazole group and 51.7% (15 of 29) of the terbinafine group (P not significant). Three itraconazole patients experienced side effects in the form of gastrointestinal problems. There were no serious adverse events and no interactions with concomitant medications recorded. Discussion Both continuous terbinafine and itraconazole pulse therapy are effective and safe in the management of dermatophyte toenail onychomycosis in people with diabetes.Keywords
This publication has 10 references indexed in Scilit:
- Global Prevalence of DiabetesDiabetes Care, 2004
- Terbinafine (LamisilR) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trialBritish Journal of Dermatology, 2002
- Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderlyJournal of the American Academy of Dermatology, 2001
- Onychomycosis and tinea pedis in patients with diabetesJournal of the American Academy of Dermatology, 2000
- Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter Canadian survey of 15,000 patientsJournal of the American Academy of Dermatology, 2000
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- The safety of itraconazole in the diabetic populationJournal of the American Podiatric Medical Association, 1999
- Safety of Itraconazole in Diabetic PatientsDermatology, 1999
- Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre surveyBritish Journal of Dermatology, 1998
- Special patient populations: Onychomycosis in the diabetic patientJournal of the American Academy of Dermatology, 1996